Skip to Content


In the US, Lurasidone (lurasidone systemic) is a member of the drug class atypical antipsychotics and is used to treat Bipolar Disorder, Borderline Personality Disorder, Schizoaffective Disorder and Schizophrenia.

US matches:



ATC (Anatomical Therapeutic Chemical Classification)


CAS registry number (Chemical Abstracts Service)


Chemical Formula


Molecular Weight


Therapeutic Category

Neuroleptic agent

Chemical Name

(3aR,4S,7R,7aS)-{(1R,2R)-2-[4-(1,2-benzisotiazol-3-yl)piperazin-1-ylmetyl]cyclohexylmetyl}hexahydro-4,7-metano-2H-isoindole-1,3-dione (WHO)

Foreign Names

  • Lurasidonum (Latin)
  • Lurasidon (German)
  • Lurasidone (French)
  • Lurasidona (Spanish)

Generic Names

Brand Names

  • Latuda
    Takeda, Poland; Takeda Pharma, Slovenia; Medius, Switzerland; Sunovion, United States; Sunovion Pharmaceuticals, Canada; Sunovion Pharmaceuticals Europe, United Kingdom; Takeda, Germany; Takeda, Finland


ISInofficial Synonym
JANJapanese Accepted Name
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name
WHOWorld Health Organization

Further information on drug naming conventions: International Nonproprietary Names.

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.